586例DEPDC5相关癫痫:变异外显率、表型谱与治疗结局
本研究通过范围综述汇总33篇文献、170个家系、586例DEPDC5变异携带者,计算年龄特异性外显率并分析基因型-表型关联。10岁时76.1%携带者发生癫痫,累积外显率64.9%;48.3%药物难治,手术者88% Engel I/II。早发癫痫与药物难治、智力障碍及MRI病灶强相关。
要点
- 10岁时76.1%携带者发生癫痫,累积外显率64.9%(95%CI 60.8%-68.7%)
- 48.3%药物难治,手术者88%达Engel I/II,支持早期手术评估
- 早发癫痫与药物难治、智力障碍及MRI病灶强相关
核心结论
- DEPDC5变异携带者癫痫外显率高,早发癫痫提示临床严重程度更高,手术可获良好结局。
研究设计与样本
- 遵循PRISMA-ScR框架的范围综述,检索PubMed截至2024年8月,纳入33篇文献、170个家系、586例变异携带者。
主要发现
- 10岁时76.1%携带者发生癫痫,累积外显率64.9%(n=380/586,95%CI 60.8%-68.7%)。
- 48.3%病例药物难治,28%可获MRI者存在皮质畸形。
- 癫痫猝死占死亡16%(n=4/25)。
- 早发癫痫与药物难治(p=2.4e-08)、智力障碍(p=2.1e-08)及MRI病灶(p=2.2e-08)强相关。
- 药物难治者中34.7%(n=35/101)接受手术,88%达Engel I或II。
临床怎么用
- 对DEPDC5相关癫痫应早期基因检测与遗传咨询,早发者需警惕药物难治及智力障碍。
- 药物难治性DEPDC5相关癫痫,尤其早发儿童,应尽早评估手术,术后多数可达Engel I/II。
局限性
- 回顾性综述,仅限发表时家系可得的基因型与表型信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: DEPDC5 variants are the most common genetic cause of focal epilepsy, often linked to focal cortical dysplasia. Despite their clinical significance, up-to-date penetrance estimates and comprehensive genotype-phenotype correlations remain limited, particularly in diverse populations. This study synthesizes data from a large cohort, including reports from Asian populations, aiming to refine penetrance estimates and to identify genotype-phenotype correlations and outcomes to inform precision care in DEPDC5-related epilepsy in diverse patient populations. METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews framework, we conducted a scoping review of PubMed for studies on "DEPDC5" published through August 2024. Studies in English, reporting genotype and phenotype information on families with DEPDC5 variants, were included; individual or sporadic cases, duplicates, and reports of recessive inheritance were excluded. Non-neurologic or nongenetic studies were excluded. Age-specific penetrance was calculated. Clinical characteristics were analyzed across individuals affected by DEPDC5-related epilepsy using the Fisher exact test and the Wilcoxon rank-sum test. RESULTS: Thirty-three publications comprising 170 families, 63.5% of which were of European ethnicity, and 586 variant carriers were included. By age 10, 76.1% of variant carriers developed epilepsy, with a cumulative penetrance of 64.9% (n = 380/586, 95% CI 60.8%-68.7%). Drug resistance occurred in 48.3% of cases, and cortical malformations were present in 28% of those with available MRI. Sudden unexpected death in epilepsy accounted for 16% (n = 4/25) of deaths among affected individuals. Early seizure onset strongly correlated with drug resistance (p = 2.4e-08, W = 2,220.5, median = 1.33 vs 7), intellectual disability (p = 2.1e-08, W = 1,525.5, median = 0.9 vs 7), and lesional MRI (p = 2.2e-08, W = 4,914.5, median = 0.5 vs 7). Among drug-resistant individuals undergoing surgery (34.7% [n = 35/101]), 88% achieved favorable outcomes (Engel I or II). DISCUSSION: By assembling the largest pooled cohort to date and including underrepresented populations, this study refines penetrance estimates and highlights the clinical severity linked to earlier seizure onset. The positive outcomes after epilepsy surgery observed in our review underscore the importance of early genetic testing and counseling, and tailored therapeutic approaches, including consideration of early surgical intervention, particularly for children with early-onset DEPDC5-related epilepsy. This retrospective review is limited to available genotype and phenotype information from families at the time of publication.
引用
- Ochoa-Urrea M, Butler EA, Bruenger T, et al. Insights Into DEPDC5-Related Epilepsy From 586 People: Variant Penetrance, Phenotypic Spectrum, and Treatment Outcomes. Neurology. 2025. PMID: 41118617. doi:10.1212/WNL.0000000000214235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。